| 产品详情 |
| Edit |   |
|---|
| Product Name | Radotinib |
|---|
| Description | Purity >98%. Radotinib is a selective second generation tyrosine kinase inhibitor that targets both the wild-type and mutant forms of Bcr-Abl, with an IC50 value of 32.5 nM in Ba/F3 human chronic myeloid leukemia cells expressing the wild-type form. Radotinib also inhibits platelet-derived growth factor receptors (PDGFRs) Alpha and Beta with IC50 values of 75.5 and 130 nM, respectively. Binding of radotinib to Bcr-Abl in vitro inhibits the phosphorylation of the downstream signaling mediator CrkL. In acute myeloid leukemia cells, in vitro treatment with radotinib at doses of 10-100 µM reduces viability, activates the mitochondrial apoptosis pathway, and promotes expression of the differentiation marker CD11b. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(2-pyrazinyl)-2-pyrimidinyl]amino]-benzamide, IY-5511 |
|---|
| Gene, Accession, CAS # | CAS: 926037-48-1 |
|---|
| Catalog # | LS-H9649 |
|---|
| Price | |
|---|
| Order / More Info | Radotinib from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|